Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 3, Issue 10, Pages e409-e409
Publisher
Springer Nature
Online
2012-10-11
DOI
10.1038/cddis.2012.149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice
- (2012) F Ke et al. CELL DEATH AND DIFFERENTIATION
- Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol
- (2012) L. Alinari et al. CLINICAL CANCER RESEARCH
- Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
- (2011) Meir Wetzler et al. CURRENT PHARMACEUTICAL DESIGN
- Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1
- (2011) Ben A. Croker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim
- (2010) L. Happo et al. BLOOD
- Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia
- (2010) R. Chen et al. BLOOD
- Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi
- (2010) Johannes Zuber et al. NATURE BIOTECHNOLOGY
- A mammalian functional-genetic approach to characterizing cancer therapeutics
- (2010) Hai Jiang et al. Nature Chemical Biology
- BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs
- (2010) E. M. Carrington et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
- (2009) David M. Lucas et al. BLOOD
- Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function
- (2009) S. M. Schoenwaelder et al. BLOOD
- Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009
- (2009) Alfonso Quintás-Cardama et al. CANCER
- Inhibitors of translation initiation as cancer therapeutics
- (2009) Lisa Lindqvist et al. Future Medicinal Chemistry
- Total Synthesis of the Potent Anticancer Aglaia Metabolites (−)-Silvestrol and (−)-Episilvestrol and the Active Analogue (−)-4′-Desmethoxyepisilvestrol
- (2009) Tim E. Adams et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia
- (2009) K D Mason et al. LEUKEMIA
- Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells
- (2009) Regina Cencic et al. LEUKEMIA RESEARCH
- XIAP discriminates between type I and type II FAS-induced apoptosis
- (2009) Philipp J. Jost et al. NATURE
- Altering Chemosensitivity by Modulating Translation Elongation
- (2009) Francis Robert et al. PLoS One
- Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
- (2009) Regina Cencic et al. PLoS One
- Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin
- (2008) Junya Kuroda et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
- (2008) Erinna F. Lee et al. JOURNAL OF CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started